The World Celebrates Ireland This St Patrick’s Day
People around the world revelled in all things Irish on 17th March – the annual global celebration of Irish culture, arts and heritage known as St Patrick’s Day.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250317647496/en/
In Dublin, around half a million people lined the streets of the capital for the St Patrick’s Festival parade, which this year has the theme of ‘Adventures’ – or ‘Eachtraí’ in Irish – representing the legendary adventurous Irish spirit, loved the world over.
St Patrick's Day is marked all over the world by the 70 million who claim links to Ireland. Celebrating Ireland’s national colour, the defining natural green lands, the Global Greenings returned for St Patrick’s Day, with iconic international landmarks lighting up in green including Niagara Falls, the Leaning Tower of Pisa, the Empire State Building, the Sky Tower in Auckland, the Royal Liver Building in Liverpool, the Sacré-Cœur in Paris, as well as the northernmost greening of a Polar Bear sculpture in the Norway’s arctic archipelago Svalbard.
2025 also marks the 10th anniversary of the establishment of a permanent walking trail at Saint Patrick’s Way. Located in the northeastern part of the Island of Ireland – the stunning 132km/82 mile trail takes in rolling hills, canal towpaths and majestic beaches connecting the Cathedral city of Armagh and Patrick’s final resting place in Downpatrick – two of locations on the island of Ireland most closely related to Saint Patrick. Saint Patrick's Way has proved to be extremely popular destination for thousands of leisure walking and pilgrimages each year and as a marker of its success a new Saint Columbanus’ Way will run along a considerable stretch of Saint Patrick’s Way from Newry to Downpatrick through the beautiful Mountains of Mourne.
Throughout Ireland there are parades and festivals over the period celebrating the nation’s Patron Saint, including the International Band Championship at the Limerick parade; the Big Festival in the Small City of Kilkenny; an exploration of Soldiers, Saints and Scholars in Waterford; Building a Better World in Cork; celebrating Queen Maeve in Sligo and an exploration of the Echoes of Killarney.
In Northern Ireland the Derry City and Strabane Spring Carnival theme of Forest, Sky and Sea celebrated the arrival of spring and brighter days, culminating in the Strabane St Patrick’s Day Parade; the Home of St Patrick Festival in Armagh which boasts a Parade in Armagh City Centre, and other Parades taking place in Belfast City, Newry and Downpatrick. Other celebrations include the annual St Patrick’s Day walk at Slemish and a programme of events at the Saint Patrick Centre in Downpatrick.
The celebration of green for St Patrick's Day is mirrored across the land itself, when nature is coming to life across the island from cities to coasts to wild mountain landscapes. Spring in Ireland is filled with daffodils and wildflowers, as well as landscapes dotted with newborn lambs. Throughout the country there are festivals, walking trails, beautiful gardens, cosy pubs and fast changing weather that heralds a beautiful rainbow!
View source version on businesswire.com: https://www.businesswire.com/news/home/20250317647496/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma18.12.2025 12:00:00 CET | Press release
BGB-B2033 is a bispecific antibody directed at GPC3 and 4-1BB; key targets in the most common liver cancerFDA Fast Track Designation reflects the potential of BGB-B2033 in an area of high unmet need BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted the Company Fast Track Designation for BGB-B2033, its GPC3x4-1BB bispecific antibody for the treatment of adult patients with hepatocellular carcinoma (HCC) with disease progression on or after prior systemic treatment. “The FDA awards Fast Track Designation to therapies that show potential to address an unmet medical need in serious or life-threatening conditions. The FDA’s decision reflects the encouraging profile of BGB-B2033 in advanced hepatocellular carcinoma, where patients continue to face limited treatment options,” said Julie Lepin, Senior Vice President and Chief Regulatory Affairs Officer at BeOne. BeOne is currentl
NHOA Energy Achieves Great Place To Work Certification in Italy, the United States and Australia18.12.2025 10:53:00 CET | Press release
NHOA Energy, global provider of utility-scale energy storage systems, announces that it has been certified Great Place To Work® in Italy, the United States, and Australia. The certification is based entirely on direct feedback from NHOA Energy employees, gathered through an independent and structured listening process. Great Place To Work® Certification™ assesses the quality of the employee experience across key dimensions such as credibility, respect, fairness, pride, and camaraderie. The results achieved by NHOA Energy reflect a corporate culture built on trust, inclusion, and the consistent commitment to valuing people within a dynamic and international environment. Employees highlighted particularly high levels of appreciation for the ethical and transparent behavior of leaders, the welcoming and inclusive approach toward new hires, and fair treatment across diversity, equity, and inclusion dimensions. A strong majority also expressed pride in working at NHOA Energy and reported a
Regnology Signs an Agreement to Acquire Moody’s Regulatory Reporting & ALM Solutions18.12.2025 10:00:00 CET | Press release
The deal further strengthens Regnology’s global position in Regulatory Reporting and significantly accelerates its expansion into new markets Regnology, a leading provider in regulatory, risk, tax, and finance reporting, as well as supervisory technology, today announced it has signed an exclusive agreement for the acquisition of Moody’s Regulatory Reporting & ALM Solutions business, inclusive of solutions for Basel III compliance, IFRS9 impairment accounting, large bank asset-liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting across more than 50 jurisdictions. By integrating Moody’s regulatory capital and liquidity capabilities with Regnology’s regulatory, risk, and finance offerings, the firm is creating a unified, scalable platform designed to meet the full spectrum of financial regulatory compliance and risk requirements. This combined strength positions Regnology as the partner of choice for financial institutions seeki
Reply Recognized as a Microsoft Azure Expert Managed Services Provider for the Sixth Consecutive Year18.12.2025 10:00:00 CET | Press release
Reply [EXM, STAR: REY] announced today it has been recognized once again as a Microsoft Azure Expert Managed Services Provider (MSP). The renewal reaffirms Reply’s proven expertise and consistent track record in delivering high-quality cloud solutions and services on the Microsoft Azure platform, powered by the deep technical expertise of its specialized companies – Cluster Reply, Solidsoft Reply and Valorem Reply. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218596617/en/ This recognition reflects the ongoing collaboration between Reply - through its companies Cluster Reply, Solidsoft Reply, and Valorem Reply - and Microsoft, supporting shared efforts to deliver value-driven services to enterprise customers. The Azure Expert MSP program is designed by Microsoft to identify and validate partners with proven capabilities in delivering end-to-end Azure services at scale. To qualify, partners must meet a strict set of requ
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 09:00:00 CET | Press release
Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half of study participants treated with zasocitinib achieved clear or almost clear skin (PASI 90), and on average about 30 percent achieved completely clear skin (PASI 100) by week 16 Zasocitinib was generally well-tolerated with a safety profile consistent with previous clinical studies Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at wee
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom